InvestorsHub Logo
Followers 58
Posts 10044
Boards Moderated 1
Alias Born 09/21/2016

Re: Jonjones325 post# 360197

Thursday, 05/12/2022 4:31:22 PM

Thursday, May 12, 2022 4:31:22 PM

Post# of 458533
jonj

Pretty much says, we think we can treat any genetic neurodevelopmental disorder. We are not disease specific and can work for all of these and for any of these symptoms.

Pretty bold! Just prescribe it and watch them improve! Ha



That is also how I read it. This (IMO) is consistent with my read of what AVXL has been driving with the S1R MOA claims. Not, one size fits all, but we will conduct evaluations over time concurrently w/the treatments (using Biomarkers customized to each indication and related/suitable tool-suite) .

So, following approval of this method, AVXL will work w/stabilized participants to (reverse engineer) selectively manage treatments for optimal efficacy. Brilliant CNS learning process. This is potential prize award winning thinking, IMO.

BTW, if I am right...the entire BIIB management team should not be allowed to handle any sharp instrument for a while.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News